Surv.m-CRA-2-G

Surv.m-CRA-2-G is a Type 2 conditionally replicating oncolytic adenovirus (mCRA) developed by Surv BioPharma. It is engineered using the company's proprietary multiple-factor-regulated Conditionally Replicating Adenovirus (mCRA) platform, which ensures high tumor specificity by requiring multiple tumor-specific factors for viral replication. This specific candidate is "armed" with a therapeutic gene to enhance its anti-tumor potency. Surv.m-CRA-2-G is designed to selectively replicate within and lyse tumor cells, particularly targeting invasive and metastatic solid cancers. While some documentation indicates preclinical status, recent pipeline updates from the sponsor suggest the program has advanced into Phase 1 clinical development.